Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Impact of Pulmonary Endarterectomy on Pulmonary Arterial Wave Propagation and Reservoir Function.

Su J, Hughes AD, Simonsen U, Nielsen-Kudsk JE, Parker KH, Howard LS, Mellemkjaer S.

Am J Physiol Heart Circ Physiol. 2019 Jun 21. doi: 10.1152/ajpheart.00181.2019. [Epub ahead of print]

PMID:
31225986
2.

Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis.

Sofianopoulou E, Kaptoge S, Gräf S, Hadinnapola C, Treacy CM, Church C, Coghlan G, Gibbs JSR, Haimel M, Howard LS, Johnson M, Kiely DG, Lawrie A, Lordan J, MacKenzie Ross RV, Martin JM, Moledina S, Newnham M, Peacock AJ, Price LC, Rhodes CJ, Suntharalingam J, Swietlik EM, Toshner MR, Wharton J, Wilkins MR, Wort SJ, Pepke-Zaba J, Condliffe R, Corris PA, Di Angelantonio E, Provencher S, Morrell NW.

Eur Respir J. 2019 May 30;53(5). pii: 1801429. doi: 10.1183/13993003.01429-2018. Print 2019 May.

PMID:
30923185
3.

Deep learning cardiac motion analysis for human survival prediction.

Bello GA, Dawes TJW, Duan J, Biffi C, de Marvao A, Howard LSGE, Gibbs JSR, Wilkins MR, Cook SA, Rueckert D, O'Regan DP.

Nat Mach Intell. 2019 Feb 11;1:95-104. doi: 10.1038/s42256-019-0019-2.

PMID:
30801055
4.

Exercise capacity reflects airflow limitation rather than hypoxaemia in patients with pulmonary arteriovenous malformations.

Gawecki F, Strangeways T, Amin A, Perks J, McKernan H, Thurainatnam S, Rizvi A, Jackson JE, Santhirapala V, Myers J, Brown J, Howard LSGE, Tighe HC, Shovlin CL.

QJM. 2019 May 1;112(5):335-342. doi: 10.1093/qjmed/hcz023.

PMID:
30657990
5.

The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.

Newnham M, South K, Bleda M, Auger WR, Barberà JA, Bogaard H, Bunclark K, Cannon JE, Delcroix M, Hadinnapola C, Howard LS, Jenkins D, Mayer E, Ng C, Rhodes CJ, Screaton N, Sheares K, Simpson MA, Southwood M, Su L, Taboada D, Traylor M, Trembath RC, Villar SS, Wilkins MR, Wharton J, Gräf S, Pepke-Zaba J, Laffan M, Lane DA, Morrell NW, Toshner M.

Eur Respir J. 2019 Mar 28;53(3). pii: 1801805. doi: 10.1183/13993003.01805-2018. Print 2019 Mar.

6.

ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.

Grünig E, Eichstaedt C, Barberà JA, Benjamin N, Blanco I, Bossone E, Cittadini A, Coghlan G, Corris P, D'Alto M, D'Andrea A, Delcroix M, de Man F, Gaine S, Ghio S, Gibbs S, Gumbiene L, Howard LS, Johnson M, Jurevičienė E, Kiely DG, Kovacs G, MacKenzie A, Marra AM, McCaffrey N, McCaughey P, Naeije R, Olschewski H, Pepke-Zaba J, Reis A, Santos M, Saxer S, Tulloh RM, Ulrich S, Vonk Noordegraaf A, Peacock AJ.

Eur Respir J. 2019 Feb 28;53(2). pii: 1800332. doi: 10.1183/13993003.00332-2018. Print 2019 Feb.

PMID:
30578391
7.

The importance of patient perspectives in pulmonary hypertension.

McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, Mehta S, Murakami N, Wong BA.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801919. doi: 10.1183/13993003.01919-2018. Print 2019 Jan.

8.

Metabolic pathways associated with right ventricular adaptation to pulmonary hypertension: 3D analysis of cardiac magnetic resonance imaging.

Attard MI, Dawes TJW, de Marvao A, Biffi C, Shi W, Wharton J, Rhodes CJ, Ghataorhe P, Gibbs JSR, Howard LSGE, Rueckert D, Wilkins MR, O'Regan DP.

Eur Heart J Cardiovasc Imaging. 2019 Jun 1;20(6):668-676. doi: 10.1093/ehjci/jey175.

9.

Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.

Rhodes CJ, Batai K, Bleda M, Haimel M, Southgate L, Germain M, Pauciulo MW, Hadinnapola C, Aman J, Girerd B, Arora A, Knight J, Hanscombe KB, Karnes JH, Kaakinen M, Gall H, Ulrich A, Harbaum L, Cebola I, Ferrer J, Lutz K, Swietlik EM, Ahmad F, Amouyel P, Archer SL, Argula R, Austin ED, Badesch D, Bakshi S, Barnett C, Benza R, Bhatt N, Bogaard HJ, Burger CD, Chakinala M, Church C, Coghlan JG, Condliffe R, Corris PA, Danesino C, Debette S, Elliott CG, Elwing J, Eyries M, Fortin T, Franke A, Frantz RP, Frost A, Garcia JGN, Ghio S, Ghofrani HA, Gibbs JSR, Harley J, He H, Hill NS, Hirsch R, Houweling AC, Howard LS, Ivy D, Kiely DG, Klinger J, Kovacs G, Lahm T, Laudes M, Machado RD, MacKenzie Ross RV, Marsolo K, Martin LJ, Moledina S, Montani D, Nathan SD, Newnham M, Olschewski A, Olschewski H, Oudiz RJ, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Rehman Z, Robbins I, Roden DM, Rosenzweig EB, Saydain G, Scelsi L, Schilz R, Seeger W, Shaffer CM, Simms RW, Simon M, Sitbon O, Suntharalingam J, Tang H, Tchourbanov AY, Thenappan T, Torres F, Toshner MR, Treacy CM, Vonk Noordegraaf A, Waisfisz Q, Walsworth AK, Walter RE, Wharton J, White RJ, Wilt J, Wort SJ, Yung D, Lawrie A, Humbert M, Soubrier F, Trégouët DA, Prokopenko I, Kittles R, Gräf S, Nichols WC, Trembath RC, Desai AA, Morrell NW, Wilkins MR; UK NIHR BioResource Rare Diseases Consortium; UK PAH Cohort Study Consortium; US PAH Biobank Consortium.

Lancet Respir Med. 2019 Mar;7(3):227-238. doi: 10.1016/S2213-2600(18)30409-0. Epub 2018 Dec 5.

10.

Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week.

Dimopoulos K, Condliffe R, Tulloh RMR, Clift P, Alonso-Gonzalez R, Bedair R, Chung NAY, Coghlan G, Fitzsimmons S, Frigiola A, Howard LS, Jenkins P, Kenny D, Li W, MacDonald ST, McCabe C, Oliver JJ, Spence MS, Szantho GV, von Klemperer K, Wilson DG, Wort SJ; CHAMPION Steering Committee.

J Am Coll Cardiol. 2018 Dec 4;72(22):2778-2788. doi: 10.1016/j.jacc.2018.08.2201. Review.

11.

Reduced plasma levels of small HDL particles transporting fibrinolytic proteins in pulmonary arterial hypertension.

Harbaum L, Ghataorhe P, Wharton J, Jiménez B, Howard LSG, Gibbs JSR, Nicholson JK, Rhodes CJ, Wilkins MR.

Thorax. 2019 Apr;74(4):380-389. doi: 10.1136/thoraxjnl-2018-212144. Epub 2018 Nov 26.

12.

Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography.

Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, Coghlan G, Kaye N, Oxborough D, Robinson S, Sandoval J, Rana BS, Siva A, Nihoyannopoulos P, Howard LS, Fox K, Bhattacharyya S, Sharma V, Steeds RP, Mathew T.

Echo Res Pract. 2018 Sep;5(3):G11-G24. doi: 10.1530/ERP-17-0071.

13.

Is right heart catheterisation still a fundamental part of the follow-up assessment of pulmonary arterial hypertension? The argument against.

Howard LS.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800996. doi: 10.1183/13993003.00996-2018. Print 2018 Jul. No abstract available.

PMID:
29973359
14.

British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism.

Howard LS, Barden S, Condliffe R, Connolly V, Davies C, Donaldson J, Everett B, Free C, Horner D, Hunter L, Kaler J, Nelson-Piercy C, O'Dowd E, Patel R, Preston W, Sheares K, Tait C.

BMJ Open Respir Res. 2018 Jun 13;5(1):e000281. doi: 10.1136/bmjresp-2018-000281. eCollection 2018.

15.

British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE).

Howard LSGE, Barden S, Condliffe R, Connolly V, Davies CWH, Donaldson J, Everett B, Free C, Horner D, Hunter L, Kaler J, Nelson-Piercy C, O-Dowd E, Patel R, Preston W, Sheares K, Campbell T.

Thorax. 2018 Jul;73(Suppl 2):ii1-ii29. doi: 10.1136/thoraxjnl-2018-211539. Epub 2018 Jun 13. Review. No abstract available.

PMID:
29898978
16.

Short-Term Hemodynamic Effects of Apelin in Patients With Pulmonary Arterial Hypertension.

Brash L, Barnes GD, Brewis MJ, Church AC, Gibbs SJ, Howard LSGE, Jayasekera G, Johnson MK, McGlinchey N, Onorato J, Simpson J, Stirrat C, Thomson S, Watson G, Wilkins MR, Xu C, Welsh DJ, Newby DE, Peacock AJ.

JACC Basic Transl Sci. 2018 Mar 28;3(2):176-186. doi: 10.1016/j.jacbts.2018.01.013. eCollection 2018 Apr.

17.

Nitric Oxide Attenuates Arterial Pulse Wave Reflection in a Vasodilator Responding Pulmonary Arterial Hypertension Patient.

Su J, Hughes AD, Simonsen U, Howard LS.

Circ Cardiovasc Interv. 2018 Mar;11(3):e006242. doi: 10.1161/CIRCINTERVENTIONS.117.006242. No abstract available.

PMID:
29870387
18.

Fractal Analysis of Right Ventricular Trabeculae in Pulmonary Hypertension.

Dawes TJW, Cai J, Quinlan M, de Marvao A, Ostrowski PJ, Tokarczuk PF, Watson GMJ, Wharton J, Howard LSGE, Gibbs JSR, Cook SA, Wilkins MR, O'Regan DP.

Radiology. 2018 Aug;288(2):386-395. doi: 10.1148/radiol.2018172821. Epub 2018 Jun 5.

19.

Exercise cardiac MRI unmasks right ventricular dysfunction in acute hypoxia and chronic pulmonary arterial hypertension.

Jaijee S, Quinlan M, Tokarczuk P, Clemence M, Howard LSGE, Gibbs JSR, O'Regan DP.

Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H950-H957. doi: 10.1152/ajpheart.00146.2018. Epub 2018 May 18.

20.

Non-vitamin K antagonist oral anticoagulants for pulmonary embolism: who, where and for how long?

Howard LS.

Expert Rev Respir Med. 2018 May;12(5):387-402. doi: 10.1080/17476348.2018.1452614. Epub 2018 Mar 26. Review.

PMID:
29542359
21.

Power of resting echocardiographic measurements to classify pulmonary hypertension patients according to European society of cardiology exercise testing risk stratification cut-offs.

Rehman MB, Garcia R, Christiaens L, Larrieu-Ardilouze E, Howard LS, Nihoyannopoulos P.

Int J Cardiol. 2018 Apr 15;257:291-297. doi: 10.1016/j.ijcard.2018.01.042. Epub 2018 Jan 31.

PMID:
29361351
22.

Thrombolysis for PE: less is more?

Howard LS.

Thorax. 2018 May;73(5):412-413. doi: 10.1136/thoraxjnl-2017-211141. Epub 2018 Jan 4. No abstract available.

PMID:
29301871
23.

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.

Ghofrani HA, Simonneau G, D'Armini AM, Fedullo P, Howard LS, Jaïs X, Jenkins DP, Jing ZC, Madani MM, Martin N, Mayer E, Papadakis K, Richard D, Kim NH; MERIT study investigators.

Lancet Respir Med. 2017 Oct;5(10):785-794. doi: 10.1016/S2213-2600(17)30305-3. Epub 2017 Sep 11.

PMID:
28919201
24.

The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension.

Price LC, Dimopoulos K, Marino P, Alonso-Gonzalez R, McCabe C, Kemnpy A, Swan L, Boutsikou M, Al Zahrani A, Coghlan GJ, Schreiber BE, Howard LS, Davies R, Toshner M, Pepke-Zaba J, Church AC, Peacock A, Corris PA, Lordan JL, Gaine S, Condliffe R, Kiely DG, Wort SJ.

Thorax. 2017 Nov;72(11):1035-1045. doi: 10.1136/thoraxjnl-2016-209725. Epub 2017 Sep 12. Review.

PMID:
28904006
25.

British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings.

O'Driscoll BR, Howard LS, Earis J, Mak V.

BMJ Open Respir Res. 2017 May 15;4(1):e000170. doi: 10.1136/bmjresp-2016-000170. eCollection 2017. No abstract available.

26.

Exertional dyspnoea in pulmonary arterial hypertension.

Dumitrescu D, Sitbon O, Weatherald J, Howard LS.

Eur Respir Rev. 2017 Sep 6;26(145). pii: 170039. doi: 10.1183/16000617.0039-2017. Print 2017 Sep 30. Review.

27.

Pulmonary artery wave propagation and reservoir function in conscious man: impact of pulmonary vascular disease, respiration and dynamic stress tests.

Su J, Manisty C, Simonsen U, Howard LS, Parker KH, Hughes AD.

J Physiol. 2017 Oct 15;595(20):6463-6476. doi: 10.1113/JP274385. Epub 2017 Sep 11.

28.

Post-tuberculous fibrosing mediastinitis: a review of the literature.

Wu Z, Jarvis H, Howard LS, Wright C, Kon OM.

BMJ Open Respir Res. 2017 May 8;4(1):e000174. doi: 10.1136/bmjresp-2016-000174. eCollection 2017. Review.

29.

Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study.

Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs JSR, Condliffe R, Elliot CA, Kiely DG, Simonneau G, Montani D, Sitbon O, Gall H, Schermuly RT, Ghofrani HA, Lawrie A, Humbert M, Wilkins MR.

Lancet Respir Med. 2017 Sep;5(9):717-726. doi: 10.1016/S2213-2600(17)30161-3. Epub 2017 Jun 15.

30.

BTS guideline for oxygen use in adults in healthcare and emergency settings.

O'Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group; BTS Emergency Oxygen Guideline Development Group.

Thorax. 2017 Jun;72(Suppl 1):ii1-ii90. doi: 10.1136/thoraxjnl-2016-209729. Review. No abstract available.

31.

Resting right ventricular function is associated with exercise performance in PAH, but not in CTEPH.

Rehman MB, Howard LS, Christiaens LP, Gill D, Gibbs JSR, Nihoyannopoulos P.

Eur Heart J Cardiovasc Imaging. 2018 Feb 1;19(2):185-192. doi: 10.1093/ehjci/jex002.

PMID:
28329277
32.

Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry.

Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland.

J Heart Lung Transplant. 2017 Jul;36(7):770-779. doi: 10.1016/j.healun.2016.12.014. Epub 2016 Dec 31.

PMID:
28190786
33.

Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study.

Dawes TJW, de Marvao A, Shi W, Fletcher T, Watson GMJ, Wharton J, Rhodes CJ, Howard LSGE, Gibbs JSR, Rueckert D, Cook SA, Wilkins MR, O'Regan DP.

Radiology. 2017 May;283(2):381-390. doi: 10.1148/radiol.2016161315. Epub 2017 Jan 16.

34.

Patient engagement and self-management in pulmonary arterial hypertension.

Graarup J, Ferrari P, Howard LS.

Eur Respir Rev. 2016 Dec;25(142):399-407. doi: 10.1183/16000617.0078-2016. Review.

35.

Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension.

Rhodes CJ, Ghataorhe P, Wharton J, Rue-Albrecht KC, Hadinnapola C, Watson G, Bleda M, Haimel M, Coghlan G, Corris PA, Howard LS, Kiely DG, Peacock AJ, Pepke-Zaba J, Toshner MR, Wort SJ, Gibbs JS, Lawrie A, Gräf S, Morrell NW, Wilkins MR.

Circulation. 2017 Jan 31;135(5):460-475. doi: 10.1161/CIRCULATIONAHA.116.024602. Epub 2016 Nov 21.

36.

Exercise physiological responses to drug treatments in chronic thromboembolic pulmonary hypertension.

Charalampopoulos A, Gibbs JS, Davies RJ, Gin-Sing W, Murphy K, Sheares KK, Pepke-Zaba J, Jenkins DP, Howard LS.

J Appl Physiol (1985). 2016 Sep 1;121(3):623-8. doi: 10.1152/japplphysiol.00087.2016. Epub 2016 Jul 14.

37.

Intravenous iron therapy in patients with idiopathic pulmonary arterial hypertension and iron deficiency.

Ruiter G, Manders E, Happé CM, Schalij I, Groepenhoff H, Howard LS, Wilkins MR, Bogaard HJ, Westerhof N, van der Laarse WJ, de Man FS, Vonk-Noordegraaf A.

Pulm Circ. 2015 Sep;5(3):466-72. doi: 10.1086/682217.

38.

Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension.

Thom HH, Capkun G, Cerulli A, Nixon RM, Howard LS.

BMC Med Res Methodol. 2015 Apr 12;15:34. doi: 10.1186/s12874-015-0007-0.

39.

Connective tissue disease-associated pulmonary arterial hypertension.

Condliffe R, Howard LS.

F1000Prime Rep. 2015 Jan 5;7:06. doi: 10.12703/P7-06. eCollection 2015. Review.

40.

[Treatment goals of pulmonary hypertension].

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:95-105. Turkish.

41.

Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors.

Charalampopoulos A, Howard LS, Tzoulaki I, Gin-Sing W, Grapsa J, Wilkins MR, Davies RJ, Nihoyannopoulos P, Connolly SB, Gibbs JS.

Pulm Circ. 2014 Dec;4(4):669-78. doi: 10.1086/678512.

42.

Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?

Howard LS, Ferrari P, Mehta S.

Eur Respir Rev. 2014 Dec;23(134):458-68. doi: 10.1183/09059180.00007514. Review.

43.

Cardiopulmonary exercise testing demonstrates maintenance of exercise capacity in patients with hypoxemia and pulmonary arteriovenous malformations.

Howard LSGE, Santhirapala V, Murphy K, Mukherjee B, Busbridge M, Tighe HC, Jackson JE, Hughes JMB, Shovlin CL.

Chest. 2014 Sep;146(3):709-718. doi: 10.1378/chest.13-2988.

44.

Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension.

Wojciak-Stothard B, Abdul-Salam VB, Lao KH, Tsang H, Irwin DC, Lisk C, Loomis Z, Stenmark KR, Edwards JC, Yuspa SH, Howard LS, Edwards RJ, Rhodes CJ, Gibbs JS, Wharton J, Zhao L, Wilkins MR.

Circulation. 2014 Apr 29;129(17):1770-80. doi: 10.1161/CIRCULATIONAHA.113.006797. Epub 2014 Feb 6.

45.

Treatment goals of pulmonary hypertension.

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D73-81. doi: 10.1016/j.jacc.2013.10.034. Review.

46.

Understanding the impact of pulmonary arterial hypertension on patients' and carers' lives.

Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A, Lombardi S, Studer S, Ferrari P.

Eur Respir Rev. 2013 Dec;22(130):535-42. doi: 10.1183/09059180.00005713. Review.

47.

Last call for the flight simulation test?

Howard LS.

Eur Respir J. 2013 Nov;42(5):1175-7. doi: 10.1183/09031936.00037813. No abstract available.

48.

Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension.

Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, Howard LS, Vonk-Noordegraaf A, Voskuyl AE.

Rheumatology (Oxford). 2014 Feb;53(2):285-92. doi: 10.1093/rheumatology/ket331. Epub 2013 Oct 22.

PMID:
24155365
49.

Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.

Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR.

Circulation. 2013 Sep 10;128(11):1214-24. doi: 10.1161/CIRCULATIONAHA.113.004136. Epub 2013 Jul 30.

PMID:
23900048
50.

Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension.

Howard LS, Watson GM, Wharton J, Rhodes CJ, Chan K, Khengar R, Robbins PA, Kiely DG, Condliffe R, Elliott CA, Pepke-Zaba J, Sheares K, Morrell NW, Davies R, Ashby D, Gibbs JS, Wilkins MR.

Pulm Circ. 2013 Jan;3(1):100-7. doi: 10.4103/2045-8932.109923.

Supplemental Content

Loading ...
Support Center